<DOC>
	<DOC>NCT03105505</DOC>
	<brief_summary>The study aims to investigate the effect of Permethrin 5% treatment on Signs and symptoms of Demodex-blepharitis in comparison to Synthomycine 5% and Fucithalmic (fusidic acid 1%) .</brief_summary>
	<brief_title>Prospective-Randomized Trial Assessing the Efficacy of Permethrin 5% for Demodex - Blepharitis Treatment in Comparison to Fucithalmic (Fusidic Acid 1%) and Synthomycine 5%</brief_title>
	<detailed_description>3 arms study. 75 patient total, 25 patients in each group. Group A (study group) patients will apply facially Permethrin 5% every night for 3 months. Group B patients will apply on the eyelids Fusidic acid 1% every night for 3 months. Group C patients will apply on the eyelids Synthomycine 5% every night for 3 months Follow up Evaluation will be made after one week, one month, two months, three months, 4 months and half a year.</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Permethrin</mesh_term>
	<mesh_term>Fusidic Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Adult (Age â‰¥18Y) individuals clinically diagnosed with Demodex blepharitis. Known sensitivity to all study medications or components. Pregnant women and individuals deemed unfit to provide informed consent. Systemic steroid use.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>